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Human papillomavirus (HPV) is a deoxyribonucleic 
acid virus from the papillomavirus family with over 200 
genomically distinct strains that infect the epithelia of 
the skin or mucosa, and most commonly cause benign 
papillomas or warts (1, 2). Recalcitrant warts due to HPV 
infection may be disfiguring and impose considerable 
life long physical and psychological distress on patients 
(3). Despite the availability of many surgical and non-
surgical therapeutic approaches, there is still a large 
demand for safe medications to treat recalcitrant warts 
due to HPV infection, especially in immunosuppressed 
patients. 
HPV vaccinations are a successful preventive measure 
used to decrease HPV infection rates, and are primarily 
used to prevent the development of cervical cancer and 
other anogenital cancers (1, 2, 4). However, these vac-
cines may emerge as a promising alternative drug for the 
treatment of recalcitrant warts (1, 4, 5). Currently, there 
are 3 licensed HPV vaccines available in the USA: Garda-
sil® (a quadrivalent vaccine targeting HPVs 6/11/16/18), 
Cervarix® (a bivalent vaccine targeting serotypes 16/18) 
and Gardasil 9® (a nonavalent vaccine targeting HPVs 
6/11/16/18/31/33/45/52/58) (1). Prophylactic vaccina-
tions, as shown in several animal models of papilloma-
virus infection, are very successful in preventing natural 
or experimental infection of skin and mucosa (6, 7). 
Although HPV vaccines are commonly utilized pro-
phylactically by eliciting a virus-neutralizing antibody 
response (thus blocking viral entry into host cells), little 
is known about their use as a treatment for existing 
HPV-related cutaneous and/or mucosal conditions (1). 
In the current case series, this study aimed to investigate 
treatment outcomes using a nonavalent HPV vaccine in 
immunosuppressed patients with recalcitrant warts. 
METHODS
A cohort review of patients with recalcitrant warts, who were 
treated with a nonavalent human papillomavirus vaccination in the 
period December to June 2019, was performed in the Department 
of Dermatology, University Hospital Bern. Recalcitrant warts are 
defined in this study as warts that last longer than 2 years and 
which have not responded to conventional local therapies, such 
as cryotherapy, salicylic acid, dinitrochlorobenzene, imiquimod, 
intralesional bleomycin, or CO2-laser ablations. One immunocom-
petent and 4 immunosuppressed patients, who were not pregnant 
and who presented with recalcitrant warts, were included in this 
study. Patients without complete medical records or regular follow-
ups were excluded from the study. The included patients read and 
signed the informed consent form. 
All patients received Gardasil® 9 (Human Papillomavirus 9-va-
lent Vaccine, Recombinant, Merck & Co., Inc.,Whitehouse Station, 
NJ, USA) in 3 doses at 0, 2 and 6 months. The clinical efficacy 
of the treatment was documented as follows: photographs were 
taken before the first vaccination, one month after the 1st vaccina-
tion, one month after the 2nd vaccination and one month after the 
third Gardasil 9® vaccination. In addition, the Dermatology Life 
Quality Index (DLQI) was evaluated before and one month after 
the 3rd Gardasil 9® vaccination. The evaluation was performed by 
2 dermatologists. The absence of all detectable lesions after the 
treatment was considered as complete resolution (CR). Disease 
regression (DR) was considered as a decrease in the size and/or 
number of more than 50% of target lesions. 
RESULTS
We report here the cases of 5 patients (3 men, 2 women, 
age range: 19–65 years) with recalcitrant warts who recei-
ved Gardasil 9® vaccine using a 3-dose schedule. The clini-
cal data is summarized in Table SI1. The mean ± standard 
deviation therapy duration of previous warts treatment 
before Gardasil 9® administration was 7.8 ± 4.6 years. 
The 4th patient, a 19-year-old woman who showed an 
impressive response to the therapy, had recalcitrant warts 
for 5 years. Treatment with cryotherapy, fluorouracil/sali-
cylic acid, diphenylcyclopropenone, and chloracetic acid 
failed to alleviate multiple warts lesions on her fingers 
and on the soles of her feet. However, improvement was 
noticed one month after the first Gardasil® vaccination, 
and nearly complete resolution was achieved 1 month 
after the 3rd Gardasil® dose (7 months after the first Gar-
dasil® dose) (Fig. 1).
All patients experienced a decrease in the number 
of lesions after the 3rd dose of Gardasil® (1 complete 
resolution (CR), 4 disease regression (DR)). No ad-
verse reactions were noted in any of the patients during 
the 3-dose treatment schedule. Aside from the optimal 
clinical response, the patients declared that they were 
able to cope better with their disease after vaccination, 
as shown by the DLQI, which improved significantly 
from 11.4 ± 3.4 to 3.0 ± 4.5 (p = 0.0114).
DISCUSSION
The results of this study showed the efficacy of a nona-
valent HPV vaccine for the management of immunosup-
pressed patients with skin warts that responded poorly to 
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other treatment strategies. This vaccine is recommended 
to prevent anogenital warts and cancers caused by certain 
types of HPV (8). 
Immunosuppressed individuals have a greater suscep-
tibility to HPV infection, typically resulting in the deve-
lopment of multiple benign tumours, such as papillomas 
(warts) of the skin and mucous membranes. Warts in 
immunocompetent individuals can spontaneously regress 
within 2 years, but in immunocompromised individuals, 
warts often persist and even spread, resulting in recal-
citrant warts (1, 9, 10). Therefore, there is still a large 
demand for safe medications to manage skin warts. HPV 
vaccinations might emerge as a promising alternative 
drug treatment for this disease, since HPV types 1–4, 7, 
8, 10, 27 and 57 are the most frequent strains of common 
skin warts, including plane warts (1, 4, 5). 
Although HPV vaccination is used as a primary 
preventative strategy, a few cases have evaluated HPV 
vaccination as a treatment (the quadrivalent, bivalent, or 
nonavalent vaccine) for patients with cutaneous warts, 
(1, 3, 11–15). Similar to our study, a recent meta-analysis 
showed that 76.6% of patients experienced a significant 
decrease in the number of lesions post-vaccine (1). Most 
of the HPV types in common skin warts are not targeted 
by the vaccine. However, its mechanism of action is still 
unclear. There is a significant homology of L1 protein 
capsids between various HPV types, which presumably 
results in cross-protection of the vaccine (3, 11). 
Our findings demonstrate a positive clinical outcome 
of the administration of a nonavalent HPV vaccine in 
the treatment of recalcitrant warts. Regarding financial 
aspects, this vaccine may be beneficial as an alternative 
treatment to treat or at least stabilize recalcitrant warts, 
especially in immunosuppressed patients. The patients 
with local therapies usually have to be treated for years 
and require many medical consultations. We assume that 
vaccination as a therapy can be a much cheaper and less 
time-consuming alternative, with a sustainable benefit.
These results therefore support the need for randomi-
zed controlled trials of therapeutic HPV vaccination for 
cutaneous warts, in order to assess the beneficial effects 
of HPV vaccines on skin warts in more detail, together 
with cost-benefit assessments, and possibly the creation 
of a vaccine specifically for skin warts.
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Fig. 1. Response to Gardasil in 
patient 4 with plantar/finger 
warts. (A) Before Gardasil®. (B) 
One month after first dose of 
Gardasil®. (C) One month after 
2nd dose of Gardasil®. (D) One 
month after 3rd dose of Gardasil®.
